CTIS2023-503390-38-00进行中（未招募）1 期
Safety, tolerability and effect of DLX-001 in healthy volunteers
Delix Therapeutics Inc.0 个研究点目标入组 106 人开始时间: 2023年2月27日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 106
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
尚未招募
1 期
Constipation relieving herbal SyrupCTRI/2019/02/017776The Himalaya Drug Company Ltd
招募中
2 期
Clinical study on subjects with impotenceCTRI/2023/10/059317Emil Pharmaceutical Industries Private Limited
招募中
2 期
Clinical study of ELED01 (supplement for general wellbeing) in healthy individualsCTRI/2024/01/061831Emil Pharmaceutical Industries Private Limited
进行中（未招募）
不适用
A phase II study of the safety and efficacy of doxycycline administered cyclically in patients suffering from Transthyretin Amiloidosis ATTR - NDTransthyretin amyloidosis ATTRMedDRA version: 6.1Level: HLGTClassification code 10034606EUCTR2006-000012-24-ITOSPEDALE POLICLINICO S. MATTEO10
进行中（未招募）
1 期
An study to investigate the combination therapy of MLN0128 plus Exemestane or Fulvestrant in post-menopausal women with advanced breast cancer or cancer that has spread and whose disease had worsened while on combination therapy with Everolimus plus Exemestane or FulvestrantER+/HER2- Advanced or Metastatic Breast CancerMedDRA version: 20.0Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2014-001921-34-BEMillennium Pharmaceuticals, Inc.128